Table of Contents
ISRN Oncology
Volume 2012 (2012), Article ID 176789, 8 pages
http://dx.doi.org/10.5402/2012/176789
Clinical Study

Gefitinib in Combination with Weekly Docetaxel in Patients with Metastatic Breast Cancer Caused Unexpected Toxicity: Results from a Randomized Phase II Clinical Trial

1Department of Oncology, Oslo University Hospital, 0424 Oslo, Norway
2Faculty of Medicine, University of Oslo, Oslo, Norway
3Institute for Cancer Research, Oslo University Hospital, 0424 Oslo, Norway
4AstraZeneca, R&D, Mereside Alderley Park, Macclesfield, UK

Received 24 January 2012; Accepted 29 February 2012

Academic Editors: A. M. Garcia-Lora and C. Nicco

Copyright © 2012 Olav Engebraaten et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. C. Palmieri and A. Jones, “The 2011 EBCTCG polychemotherapy overview,” The Lancet, vol. 379, no. 9814, pp. 390–392, 2012. View at Google Scholar
  2. M. J. Piccart-Gebhart, M. Procter, B. Leyland-Jones et al., “Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer,” The New England Journal of Medicine, vol. 353, no. 16, pp. 1659–1672, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. I. Smith, M. Procter, R. D. Gelber et al., “2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial,” The Lancet, vol. 369, no. 9555, pp. 29–36, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. M. F. Rimawi, P. B. Shetty, H. L. Weiss et al., “Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes,” Cancer, vol. 116, no. 5, pp. 1234–1242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. M. N. Dickler, M. A. Cobleigh, K. D. Miller, P. M. Klein, and E. P. Winer, “Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 115, no. 1, pp. 115–121, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. G. von Minckwitz, W. Jonat, P. Fasching et al., “A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 89, no. 2, pp. 165–172, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Baselga, J. Albanell, A. Ruiz et al., “Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer,” Journal of Clinical Oncology, vol. 23, no. 23, pp. 5323–5333, 2005. View at Google Scholar
  9. F. M. Sirotnak, M. F. Zakowski, V. A. Miller, H. I. Scher, and M. G. Kris, “Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase,” Clinical Cancer Research, vol. 6, no. 12, pp. 4885–4892, 2000. View at Google Scholar · View at Scopus
  10. F. Ciardiello, R. Caputo, R. Bianco et al., “Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor,” Clinical Cancer Research, vol. 7, no. 5, pp. 1459–1465, 2001. View at Google Scholar · View at Scopus
  11. F. Ciardiello, T. Troiani, F. Caputo et al., “Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer,” British Journal of Cancer, vol. 94, no. 11, pp. 1604–1609, 2006. View at Publisher · View at Google Scholar · View at Scopus
  12. S. K. Dennison, S. A. Jacobs, J. W. Wilson et al., “A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer,” Investigational New Drugs, vol. 25, no. 6, pp. 545–551, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. Nabholtz, H. J. Senn, W. R. Bezwoda et al., “Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group,” Journal of Clinical Oncology, vol. 17, no. 5, pp. 1413–1424, 1999. View at Google Scholar
  14. J. Sjöström, C. Blomqvist, H. Mouridsen et al., “Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group,” European Journal of Cancer, vol. 35, no. 8, pp. 1194–1201, 1999. View at Publisher · View at Google Scholar · View at Scopus
  15. U. Gatzemeier, A. Pluzanska, A. Szczesna et al., “Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva lung cancer investigation trial,” Journal of Clinical Oncology, vol. 25, no. 12, pp. 1545–1552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. G. Giaccone, R. S. Herbst, C. Manegold et al., “Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 777–784, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. R. S. Herbst, G. Giaccone, J. H. Schiller et al., “Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 2,” Journal of Clinical Oncology, vol. 22, no. 5, pp. 785–794, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. R. S. Herbst, D. Prager, R. Hermann et al., “TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 5892–5899, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Kelly, K. Chansky, L. E. Gaspar et al., “Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2450–2456, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. D. Cameron, M. Casey, M. Press et al., “A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses,” Breast Cancer Research and Treatment, vol. 112, no. 3, pp. 533–543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. C. E. Geyer, J. Forster, D. Lindquist et al., “Lapatinib plus capecitabine for HER2-positive advanced breast cancer,” The New England Journal of Medicine, vol. 355, no. 26, pp. 2733–2743, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. H. J. Burstein, J. Manola, J. Younger et al., “Docetaxel administered on a weekly basis for metastatic breast cancer,” Journal of Clinical Oncology, vol. 18, no. 6, pp. 1212–1219, 2000. View at Google Scholar · View at Scopus
  23. J. D. Hainsworth, H. A. Burris III, D. A. Yardley et al., “Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a minnie pearl cancer research network phase II trial,” Journal of Clinical Oncology, vol. 19, no. 15, pp. 3500–3505, 2001. View at Google Scholar · View at Scopus
  24. H. J. Stemmler, K. Gutschow, H. Sommer et al., “Weekly docetaxel (Taxotere) in patients with metastatic breast cancer,” Annals of Oncology, vol. 12, no. 10, pp. 1393–1398, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. D. J. Sargent and R. M. Goldberg, “A flexible design for multiple armed screening trials,” Statistics in Medicine, vol. 20, no. 7, pp. 1051–1060, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Edvardsen, P. F. Brunsvig, H. Solvang et al., “SNPs in genes coding for ROS metabolism and signalling in association with docetaxel clearance,” Pharmacogenomics Journal, vol. 10, no. 6, pp. 513–523, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Edvardsen, G. Irene Grenaker Alnaes, A. Tsalenko et al., “Experimental validation of data mined single nucleotide polymorphisms from several databases and consecutive dbSNP builds,” Pharmacogenetics and Genomics, vol. 16, no. 3, pp. 207–217, 2006. View at Google Scholar
  28. A. Tsalenko, A. Ben-Dor, N. Cox, and Z. Yakhini, “Methods for analysis and visualization of SNP genotype data for complex diseases,” Pacific Symposium on Biocomputing, pp. 548–561, 2003. View at Google Scholar · View at Scopus
  29. A. Eniu, F. M. Palmieri, and E. A. Perez, “Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer,” Oncologist, vol. 10, no. 9, pp. 665–685, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Forsythe and K. Faulkner, “Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer,” Drug Safety, vol. 27, no. 14, pp. 1081–1092, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. Y. Zhu, H. Yang, Q. Chen et al., “Modulation of DNA damage/DNA repair capacity by XPC polymorphisms,” DNA Repair, vol. 7, no. 2, pp. 141–148, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. A. H. Klopp, A. Jhingran, L. Ramdas et al., “Gene expression changes in cervical squamous cell carcinoma after initiation of chemoradiation and correlation with clinical outcome,” International Journal of Radiation Oncology Biology Physics, vol. 71, no. 1, pp. 226–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Gu, H. Zhao, C. P. Dinney et al., “Nucleotide excision repair gene polymorphisms and recurrence after treatment for superficial bladder cancer,” Clinical Cancer Research, vol. 11, no. 4, pp. 1408–1415, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. A. DeMichele, R. Aplenc, J. Botbyl et al., “Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5552–5559, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. W. P. Petros, P. J. Hopkins, S. Spruill et al., “Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer,” Journal of Clinical Oncology, vol. 23, no. 25, pp. 6117–6125, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. I. Royer, B. Monsarrat, M. Sonnier, M. Wright, and T. Cresteil, “Metabolism of docetaxel by human cytochromes P450: interactions with paclitaxel and other antineoplastic drugs,” Cancer Research, vol. 56, no. 1, pp. 58–65, 1996. View at Google Scholar · View at Scopus
  37. J. Li, M. O. Karlsson, J. Brahmer et al., “CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors,” Journal of the National Cancer Institute, vol. 98, no. 23, pp. 1714–1723, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. S. D. Baker, J. Verweij, G. A. Cusatis et al., “Pharmacogenetic pathway analysis of docetaxel elimination,” Clinical Pharmacology and Therapeutics, vol. 85, no. 2, pp. 155–163, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Tran, V. Jullien, J. Alexandre et al., “Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms,” Clinical Pharmacology and Therapeutics, vol. 79, no. 6, pp. 570–580, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. S. M. Tsai, C. Y. Lin, S. H. Wu et al., “Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms,” Clinica Chimica Acta, vol. 404, no. 2, pp. 160–165, 2009. View at Publisher · View at Google Scholar · View at Scopus